Elite Pharmaceuticals Files 8-K with Financials and Exhibits

TL;DR

Elite Pharma filed an 8-K on 8/8/25 for financials and exhibits.

AI Summary

Elite Pharmaceuticals, Inc. filed an 8-K on August 8, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Elite Pharmaceuticals is providing updated financial information and exhibits to the SEC, which is standard practice for public companies to maintain transparency.

Risk Assessment

Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate negative or positive material changes.

Key Players & Entities

• ELITE PHARMACEUTICALS INC /NV/ (company) — Registrant
• August 8, 2025 (date) — Date of Report
• 165 Ludlow Avenue, Northvale, New Jersey 07647 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01. R

Filing Documents

• form8-k.htm (8-K) — 41KB
• ex99-1.htm (EX-99.1) — 12KB
• ex99-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-25-011765.txt ( ) — 224KB
• eltp-20250808.xsd (EX-101.SCH) — 3KB
• eltp-20250808_lab.xml (EX-101.LAB) — 33KB
• eltp-20250808_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 8, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC . ELITE PHARMACEUTICALS INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 165 Ludlow Avenue , Northvale , New Jersey 07647 (Address of principal executive offices) (201) 750-2646 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01. Regulation FD Disclosure. On August 8, 2025, Elite Pharmaceuticals, Inc. ("Elite" or the "Company") issued a press release announcing that the company will host a conference call to discuss its financial results for the first quarter of fiscal year 2026 ended June 30, 2025, on Friday, August 15, 2025, at 11:30 AM EDT. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Conference Call Information Date: August 15, 2025 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic) 1-973-528-0008 (international) Conference number: 98840 Questions: dianne@elitepharma.com General questions by 5:00 PM EDT on Wednesday, August 13, 2025 Financial questions by 7:00 PM EDT on Thursday, August 14, 2025 The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, "Results of Operations and Financial Condition," Item 7.01, "Regulation FD Disclosure" and Item 9.01 "Financial Statements and Exhibits" of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 8, 2025 ELITE PHARMACEUTICALS, INC. By: /s/ Nasrat Hakim Nasrat Hakim, President and CEO

View Full Filing

View this 8-K filing on SEC EDGAR